Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
An Observational Study of the Efficacy and Safety of Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Le Qu, M. D.
- Phone Number: +86 15720625951
- Email: septsoul@hotmail.com
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 401520
- Recruiting
- Jinling Hospital
-
Contact:
- Le Qu, M. D.
- Phone Number: +86 15123894157
- Email: septsoul@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects have fully understood and voluntarily signed the informed consent form (ICF);
- 18-80 years old (at the time of signing the informed consent); Both men and women; ECOG PS score: 0-1;
- Renal cell carcinoma with clear cell components confirmed histologically or cytopathologically, including unresectable or recurrent metastatic renal cell carcinoma dominated by clear cell components;
- According to RECIST (version 1.1), there are targets that are considered to be observable;
- The main organs function well.
Exclusion Criteria:
- A history of malignancies other than the disease studied within the past 5 years, other than malignancies that are expected to be cured with treatment (including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or breast ductal carcinoma in situ treated with radical surgery);
- Systemic treatment with other antitumor agents, including targeted agents, immunotherapy agents and their combination regimens (eligible for inclusion after 5 half-lives), local antitumor therapy, or clinical investigational drug or device therapy within 4 weeks prior to the initial study;
- Had major surgery within 4 weeks prior to initial study dosing (as judged by the investigator) or was in recovery;
- A history of severe drug allergy, including but not limited to antibody drugs;
- Patients with contraindications for immunotherapy restart;
- A known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation may require long-term adrenal corticosteroid therapy. Patients with thyroid, suprarenal, or hypopituitarism that can be controlled by hormone replacement therapy alone, type 1 diabetes mellitus, and psoriasis or vitiligo that do not require systemic treatment are eligible to participate in this study;
- Toxicity did not resolve after previous antitumor therapy, i.e., regression to baseline, NCI-CTCAE 5.0 level 0-1 (except for alopecia), or levels specified in inclusion/exclusion criteria. Irreversible toxicity (e.g., hearing loss) that is not reasonably expected to be aggravated by the drug under study may be included in the study;
- Have central nervous system metastases and/or cancerous meningitis;
- Known history of clinically significant liver disease, including those infected with viral hepatitis activity;
- Patients with uncontrolled third space effusion requiring repeated drainage, such as pleural effusion, ascites, pericardial effusion, etc. (Patients with no need to drain effusion or no significant increase in effusion after 3 days of stopping drainage could be included);
- Patients with any severe and/or uncontrolled disease;
- Renal failure requires hemodialysis or peritoneal dialysis;
- Have or have a suspected active autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.;
- History of live attenuated vaccine vaccination within 4 weeks prior to the initial study or expected live attenuated vaccine vaccination during the study period;
- Those who have a history of psychotropic drug abuse and cannot abstain or have a history of mental disorders;
- Other severe, acute, or chronic medical or psychiatric conditions or laboratory abnormalities, as determined by the investigator, that may increase the risks associated with study participation or that may interfere with the interpretation of the study results.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental cohort.
Subjects who progressed after first-line treatment and switched to second-line treatment regimens including vorolanib.
The first-line treatment which patients received can be other tyrosine kinase inhibitors (TKIs) or TKIs combined with immunotherapy drugs.
Provided vorolanib is contained in the second-line regimen, the patient then can be considered for inclusion in the study.
|
For those patients who have reached the end point of the study, survival data during treatment with vorolanib is obtained for retrospective analysis.
The patients who are still on treatment with vorolanib are followed up closely and survival data is obtained for prospective analysis.
After summarizing the results of retrospective and prospective studies, relevant efficacy and safety conclusions will be drawn.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Progression Free Survival (PFS)
Time Frame: From enrollment to the end of treatment at 12 weeks.
|
From enrollment to the end of treatment at 12 weeks.
|
|
Treatment Related Adverse Events (TRAEs)
Time Frame: From enrollment to up to 90 days after treatment at 12 weeks or reported.
|
From enrollment to up to 90 days after treatment at 12 weeks or reported.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Overall Survival (OS)
Time Frame: From enrollment to the end of treatment at 12 weeks.
|
From enrollment to the end of treatment at 12 weeks.
|
|
Objective Response Rate (ORR)
Time Frame: From enrollment to the end of treatment at 12 weeks.
|
From enrollment to the end of treatment at 12 weeks.
|
|
Disease Control Rate (DCR)
Time Frame: From enrollment to the end of treatment at 12 weeks.
|
From enrollment to the end of treatment at 12 weeks.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Yuxiu Liu, M. D., Jinling Hospital, China
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Female Urogenital Diseases and Pregnancy Complications
- Neoplasms by Histologic Type
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Urogenital Diseases
- Neoplasms
- Carcinoma
- Urologic Diseases
- Carcinoma, Renal Cell
- Urologic Neoplasms
- Kidney Diseases
- Kidney Neoplasms
- Urogenital Neoplasms
- Male Urogenital Diseases
- Female Urogenital Diseases
Other Study ID Numbers
Other Study ID Numbers
- 2024DZKY-074-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.